Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1994:13 Suppl 2:S3-8.
doi: 10.1007/BF01973595.

Growth factors and the molecular control of haematopoiesis

Affiliations
Review

Growth factors and the molecular control of haematopoiesis

T M Dexter et al. Eur J Clin Microbiol Infect Dis. 1994.

Abstract

In the absence of appropriate growth factors, for example interleukin-3 or GM-CSF, cultured bone marrow stem cells die by a process known as apoptosis or programmed cell death. Apoptosis may occur in vivo when concentrations of specific growth factors are limiting and may be a means of regulating cell numbers. Growth factors are also essential for proliferation of bone marrow stem cells but differentiation can occur, provided there is a survival stimulus in the absence of growth factors. Combinations of growth factors may be synergistic in stimulating the survival and proliferation of multipotent stem cells. Although neither stem cell factor, nor GM-CSF alone can significantly induce the proliferation of stem cells, the combination induces the proliferation of these cells. Committed progenitor cells such as granulocyte-macrophage colony-forming cells, however, are stimulated to proliferate by GM-CSF alone, while stem cell factor in combination with GM-CSF results in only a slight additive effect. To date, most research has concentrated on the growth stimulatory factors. GM-CSF has an important role in the reversal of chemotherapy-induced myelosuppression in cancer patients and in other bone marrow disorders. A number of growth inhibitory molecules have now been identified, such as macrophage inhibitory protein-1 alpha. In the future, it is possible that improvements in cure rates may be achieved in cancer patients by combining the growth inhibitory factors with the stimulatory factors. Inhibitory factors may be given before chemotherapy to prevent toxicity and stimulatory factors may be given afterwards to treat neutropenic patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blood. 1993 Dec 15;82(12):3515-23 - PubMed
    1. Immunol Today. 1987;8(5):134-40 - PubMed
    1. Cell. 1982 Jan;28(1):71-81 - PubMed
    1. Cell. 1993 Sep 10;74(5):823-32 - PubMed
    1. Exp Hematol. 1989 Jun;17(5):455-9 - PubMed

MeSH terms

Substances

LinkOut - more resources